Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data
Celine Yeh(Memorial Sloan Kettering Cancer Center), Susan E. Bates(The Nature Conservancy), Tito Fojo(James J. Peters VA Medical Center), Marc Ychou(Université de Montpellier), Thierry Conroy(Inserm), Gulam A. Manji(NewYork–Presbyterian Hospital), Elizabeth M. Hecht(Cornell University), Keith Sigel(Icahn School of Medicine at Mount Sinai), Rachael A. Safyan(Columbia University Irving Medical Center), Ruth White(Columbia University Irving Medical Center), Stephen M. Schreibman(Columbia University Irving Medical Center), John A. Chabot(Columbia University Irving Medical Center), Béata Juzyna(UniCancer Group), Yvonne M. Saenger(Penn Presbyterian Medical Center), Mengxi Zhou(Guangdong Provincial Center for Disease Control and Prevention), Daniel D. Von Hoff(Translational Genomics Research Institute), Gayle Jameson(HonorHealth)
Cited by 11
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k